Ubs Group Ag Lipocine Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$0.3 - $0.58 $4,095 - $7,916
13,650 Added 119.08%
25,113 $8,000
Q4 2022

Feb 08, 2023
BUY
$0.37 - $8.65 $4,056 - $94,829
10,963 Added 2192.6%
11,463 $4,000
Q2 2022

Aug 10, 2022
SELL
$0.73 - $1.34 $5,009 - $9,195
-6,862 Reduced 93.21%
500 $0
Q1 2022

May 16, 2022
BUY
$0.89 - $1.85 $2,992 - $6,219
3,362 Added 84.05%
7,362 $10,000
Q4 2021

Feb 14, 2022
BUY
$0.99 - $1.2 $1,906 - $2,311
1,926 Added 92.86%
4,000 $4,000
Q3 2021

Nov 15, 2021
SELL
$1.08 - $1.49 $5,087 - $7,019
-4,711 Reduced 69.43%
2,074 $2,000
Q2 2021

Aug 13, 2021
BUY
$1.17 - $1.59 $5,598 - $7,608
4,785 Added 239.25%
6,785 $9,000
Q1 2021

May 12, 2021
BUY
$1.38 - $2.28 $690 - $1,140
500 Added 33.33%
2,000 $3,000
Q3 2020

Nov 12, 2020
BUY
$1.21 - $2.23 $605 - $1,115
500 Added 50.0%
1,500 $2,000
Q2 2020

Jul 31, 2020
SELL
$0.42 - $1.26 $958 - $2,874
-2,281 Reduced 69.52%
1,000 $1,000
Q1 2020

May 01, 2020
SELL
$0.32 - $0.77 $872 - $2,099
-2,726 Reduced 45.38%
3,281 $1,000
Q4 2019

Feb 14, 2020
BUY
$0.32 - $3.15 $1,602 - $15,772
5,007 Added 500.7%
6,007 $2,000
Q3 2019

Nov 14, 2019
SELL
$1.79 - $3.33 $6,295 - $11,711
-3,517 Reduced 77.86%
1,000 $3,000
Q2 2019

Aug 14, 2019
BUY
$1.43 - $2.32 $1,833 - $2,974
1,282 Added 39.63%
4,517 $9,000
Q1 2019

May 14, 2019
BUY
$1.46 - $2.33 $4,723 - $7,537
3,235 New
3,235 $7,000
Q4 2018

Feb 14, 2019
SELL
$1.07 - $1.63 $7,336 - $11,176
-6,857 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$1.31 - $1.63 $5,642 - $7,020
4,307 Added 168.9%
6,857 $10,000
Q2 2018

Aug 14, 2018
SELL
$1.06 - $1.78 $11,803 - $19,820
-11,135 Reduced 81.37%
2,550 $4,000
Q1 2018

May 15, 2018
BUY
$1.18 - $3.46 $12,931 - $37,918
10,959 Added 402.02%
13,685 $21,000
Q4 2017

Feb 14, 2018
SELL
$3.36 - $4.35 $6,599 - $8,543
-1,964 Reduced 41.88%
2,726 $10,000
Q3 2017

Nov 14, 2017
BUY
$3.67 - $4.19 $16,555 - $18,901
4,511 Added 2520.11%
4,690 $19,000
Q2 2017

Aug 14, 2017
SELL
N/A
-927 Reduced 83.82%
179 $1,000
Q1 2017

Nov 14, 2017
BUY
N/A
1,106
1,106 $4,000

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $335M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email